Drug Profile
Research programme: cachexia therapeutics - Halsa Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aston University
- Developer Halsa Pharmaceuticals
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cachexia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cachexia in USA (Parenteral)
- 18 Feb 2010 Preclinical trials in Cachexia in USA (Parenteral)